Please login to the form below

Not currently logged in
Email:
Password:

Amgen and Takeda lung drug fails trial

Amgen and Takeda have revealed that its lung cancer drug motesanib has failed to meet its endpoint in a phase III trial
Amgen and Takeda have revealed that its lung cancer drug motesanib has failed to meet its endpoint in a phase III trial. 

The drug failed to demonstrate an improvement in overall survival rate when combined with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

In this trial, as in earlier trials of motesanib, the patients who received the drug were also more likely to experience serious adverse events more frequently than those who were given a placebo. Among the adverse events reported were hypertension and bleeding disorders.

Roger M Perlmutter, executive vice president of research and development at Amgen, said: "We are disappointed with the results from this trial, but look forward to further analysis of the data which may ultimately help inform future research in this area."

No decision has been made about continuing development.

31st March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics